Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study.
BACKGROUND
Recent studies demonstrate that botulinum toxin type A (BTX-A) decreases palmar hyperhidrosis.


OBJECTIVE
To evaluate the efficacy and safety of BTX-A for palmar hyperhidrosis.


METHODS
Patients (n = 19) received injections of placebo (normal saline) in one hand and BTX-A in the other. Assessments included gravimetric measurement of sweat production and physician's and patient's rating of severity. Safety evaluations included measuring grip strength. Preliminary 28-day results are reported.


RESULTS
The mean percentage decrease in gravimetric measurement at day 28 was significantly greater with BTX-A versus placebo. One hundred percent of 17 patients rated the treatment as successful, while only 12% (2/17) rated placebo injection successful. Grip and hand strength were unchanged with either treatment. Only 21% (4/19) reported mild adverse events.


CONCLUSIONS
BTX-A injections produce significant improvements in palmar hyperhidrosis without a concomitant decrease in grip or dexterity, or the occurrence of serious adverse events.
Lowe
Nicholas J
NJ
Clinical Research Specialists, Santa Monica, CA 90404, USA.
Yamauchi
Paul S
PS
Lask
Gary P
GP
Patnaik
Rickie
R
Iyer
Shilesh
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004311:Double-Blind Method; D006225:Hand; D018737:Hand Strength; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D012720:Severity of Illness Index; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A